True Health Medical (02697) witnessed a sharp intraday surge of over 14%, reaching a peak of 850 Hong Kong dollars and setting a new record high since its listing. As of the time of writing, the stock was up 12.08%, trading at 835 Hong Kong dollars, with a trading volume of 37.8084 million Hong Kong dollars.

Recently, the First Affiliated Hospital of Guangzhou University of Chinese Medicine introduced an AI-powered thoracic surgery robot. This system uses artificial intelligence to precisely locate small lung nodules, upgrading the diagnostic process from traditional "blind screening" to "targeted precision." This advancement significantly improves the efficiency of early-stage lung cancer diagnosis and treatment, offering patients more accurate and less invasive therapeutic options.

Industry insiders believe that as technologies such as AI image recognition, 3D reconstruction, and robotic-assisted interventions continue to mature, the medical robotics industry is accelerating its entry into commercial application phases. This covers high-value fields including lung cancer, orthopedics, and neurosurgery, presenting broad growth prospects for the sector.

It is reported that benefiting from the trend of medical智能化 upgrade, True Health Medical, known as the "first share of puncture surgery robots," is continuously advancing its布局 in artificial intelligence and digital healthcare. The company is refining its product offerings in areas such as smart healthcare, AI-assisted diagnosis and treatment, and medical信息化. It is actively promoting the application of AI technology in hospital clinical settings.

As the country continues to drive digital healthcare construction and the rapid implementation of new technologies like AI medical robots and precision diagnostics, True Health Medical is poised to benefit from the rising industry sentiment, potentially unlocking further long-term growth opportunities.